Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room B3B85, MD, 20892, Bethesda, USA.
Curr Urol Rep. 2020 Oct 26;21(12):55. doi: 10.1007/s11934-020-01005-x.
To summarize the role of prostate MRI in the assessment and treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS).
BPH/LUTS is a very common source of morbidity in aging men. mpMRI has become an increasingly popular modality for prostate imaging due to its ability to provide exceptional anatomic detail. This has allowed for MRI classification of BPH and detailed assessment of response to various BPH treatment modalities, including simple prostatectomy and transurethral resection of the prostate as well as newer methods like UroLift and prostatic artery embolization. MRI will continue to be a useful tool in the diagnosis and management of BPH/LUTS and provides useful information about the efficacy of a variety of available treatment options. Further studies are needed to fully characterize the effects of newer BPH interventions on mpMRI.
总结前列腺磁共振成像(mpMRI)在评估和治疗良性前列腺增生(BPH)及相关下尿路症状(LUTS)中的作用。
BPH/LUTS 是老年男性发病率非常高的一个原因。mpMRI 因其提供卓越的解剖细节的能力,已成为前列腺成像中越来越受欢迎的模式。这使得能够对 BPH 进行 MRI 分类,并对各种 BPH 治疗方法的反应进行详细评估,包括简单的前列腺切除术和经尿道前列腺切除术以及较新的方法,如 UroLift 和前列腺动脉栓塞术。MRI 将继续成为诊断和管理 BPH/LUTS 的有用工具,并提供有关各种现有治疗选择的疗效的有用信息。需要进一步的研究来充分描述新的 BPH 干预措施对 mpMRI 的影响。